Donald Trump’s recent state visit to the UK delivered a headline £150 billion package of US investment commitments spanning different industries. The most significant pledge for our sector was a £3.9 billion investment from Prologis, the real estate and logistics giant, aimed at strengthening the UK’s life sciences sector.
Prologis confirmed it will expand its footprint at the Cambridge Biomedical Campus, developing new lab, trials and diagnostics facilities alongside advanced manufacturing hubs in Daventry and elsewhere. The project is designed to attract global pharmaceutical and diagnostics firms, reinforcing Cambridge’s status as a leading cluster for biomedical research and innovation.
The president’s trip coincided with the signing of the UK-US Tech Prosperity Deal, focused on developing the fastest growing technologies like AI, quantum, and nuclear. This could benefit millions of patients as diagnostics expect to become increasingly reliant on AI in future to provide even faster diagnoses.
With the UK life sciences industry having suffered recent setbacks including Merck’s scrapped UK expansion plans, the government has framed the £150bn headline figure as proof that Britain remains a magnet for international investment in high-value sectors such as health, science and technology.
